Anzemet and Erbitux drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Anzemet (dolasetron mesylate) and Erbitux (cetuximab). Common drug interactions include cardio-respiratory arrest among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Anzemet and Erbitux. It is created by eHealthMe based on reports of 50 people who take the same drugs from the FDA, and is updated regularly.

What is Anzemet?

Anzemet has active ingredients of dolasetron mesylate. eHealthMe is studying from 2,603 Anzemet users. Check the latest studies of Anzemet.

What is Erbitux?

Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

50 people who take Anzemet and Erbitux together, and have interactions are studied.

What are the common drug interactions of Anzemet and Erbitux, by gender? *:

female:

Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
Chest discomfort
Chills (felling of cold)
Colon cancer recurrent
Conjunctivitis (pink eye)
Decreased appetite
Diplopia (double vision)
Dysuria (painful or difficult urination)
Eye redness
Eyelid margin crusting (crusting at the lid margins, generally worse on waking)

male:

Death
Fatigue (feeling of tiredness)
Anaphylactic reaction (serious allergic reaction)
Cardiac disorder
Coma (state of unconsciousness lasting more than six hours)
Eye pruritus (eye itching)
Injection site discolouration
Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking)
Mucosal inflammation (infection of mucous membrane)
Stomatitis (inflammation of mucous membrane of mouth)

What are the common drug interactions of Anzemet and Erbitux, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Acne (skin problems that cause pimples)
Dry skin
Hypoaesthesia (reduced sense of touch or sensation)

40-49:

Hypotension (abnormally low blood pressure)
Injection site discolouration
Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking)
Mucosal inflammation (infection of mucous membrane)
Pyrexia (fever)
Stomatitis (inflammation of mucous membrane of mouth)
Abdominal pain
Body temperature increased
Diplopia (double vision)
Epistaxis (bleed from the nose)

50-59:

Nephrolithiasis (calculi in the kidneys)
Neutropenia (an abnormally low number of neutrophils)
Obstructive airways disorder (a progressive disease that makes it hard to breathe)
Oedema peripheral (superficial swelling)
Oxygen saturation decreased
Palmar erythema (reddening of the palms at the thenar and hypothenar eminences)
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Pyrexia (fever)
Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
Rash papular (redness with papule)

60+:

Hypotension (abnormally low blood pressure)
Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
Urticaria (rash of round, red welts on the skin that itch intensely)
Abdominal pain
Abdominal pain lower
Anaemia (lack of blood)
Arthralgia (joint pain)
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Asthenia (weakness)
Bone pain

What are the existing conditions these people have? *

Colon Cancer: 14 people, 28.00%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 9 people, 18.00%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 7 people, 14.00%
Oral Cancer (mouth cancer): 4 people, 8.00%
Neoplasm Malignant (cancer tumour): 3 people, 6.00%
Nausea (feeling of having an urge to vomit): 3 people, 6.00%

* Approximation only. Some reports may have incomplete information.

Do you take Anzemet and Erbitux?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously